Will the Biotech Rebound Run into Pricing Policy Obstacles? episode artwork

EPISODE · Feb 27, 2024 · 13 MIN

Will the Biotech Rebound Run into Pricing Policy Obstacles?

from Pathfinders in Biopharma

Drug pricing is already an issue in the U.S. election campaign. Brian Abrahams, MD and Head of Biotech Research at RBC Capital Markets joins the Pathfinders in Biopharma podcast to consider how this, together with other policy developments in the U.S. and worldwide, might affect a resurgent biotech sector.

Episode metadata supplied by the publisher feed · Published Feb 27, 2024

Embed this episode

NOW PLAYING

Will the Biotech Rebound Run into Pricing Policy Obstacles?

0:00 13:25

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Pathfinders in Biopharma?

This episode is 13 minutes long.

When was this Pathfinders in Biopharma episode published?

This episode was published on February 27, 2024.

Can I download this Pathfinders in Biopharma episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!